Emgality vs Ajovy
A side-by-side look at two neurology medications advertised on TV. Informational only — not medical advice.
| US Emgality | US Ajovy | |
|---|---|---|
| Generic name | galcanezumab | fremanezumab |
| Drug class | CGRP Antagonist (Biologic) | CGRP Antagonist (Biologic) |
| Treats | Migraine prevention, cluster headache | Migraine prevention |
| Category | Neurology | Neurology |
| Manufacturer | Eli Lilly | Teva |
| Year approved | 2018 | 2018 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $110M | $70M |
| Common side effects | Injection site reactions, Constipation, Itching, Allergic reactions | Injection site reactions, Allergic reactions |
Frequently asked questions
Is Emgality or Ajovy better?
Neither is universally "better." Emgality (galcanezumab) and Ajovy (fremanezumab) are both used for neurology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Emgality and Ajovy?
Emgality is a CGRP Antagonist (Biologic) made by Eli Lilly, while Ajovy is a CGRP Antagonist (Biologic) made by Teva. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Emgality has the larger estimated TV advertising budget of the two.